BeiGene is a global biotechnology company that is discovering and developing innovative oncology treatments that are more accessible and affordable to cancer patients worldwide. They have a commercial presence in more than 60 markets, with products treating various forms of cancer, and their broad and deep pipeline has the potential to address 80 percent of cancers by incidence. 

They have grown rapidly since our founding in 2010 to more than 9,000 colleagues working on five continents, including more than 950 oncology researchers, one of the largest such teams in the industry. They have administrative offices in Basel, Beijing and Cambridge, U.S. 

As they have grown, they have also evolved. In 2022, the company published its first Environmental, Social and Governance report and introduced “Change in the Cure,” a framework that provides a path for helping us shape a better world by advancing global health, improving access to medicines and ensuring quality in all their work. They have also introduced initiatives to improve work/life balance for their colleagues.